Richard Miller Biography and Net Worth
Dr. Miller was co-founder and CEO of Pharmacyclics, where he led the initial discovery and development efforts for ibrutinib. Prior to that, he was a co-founder, Vice President and Director of IDEC (which merged to form Biogen IDEC, now Biogen), where he led research efforts on lymphoma culminating in the development of rituximab. He has also founded other private and public biotech companies. Dr. Miller received an M.D. from the State University of New York Medical School. He is a board-certified oncologist and is currently Adjunct Clinical Professor of Medicine (oncology) at Stanford University Medical Center.
What is Richard A. Miller 's net worth?
The estimated net worth of Richard A. Miller is at least $1.20 million as of December 13th, 2022. Dr. Miller owns 1,480,119 shares of Corvus Pharmaceuticals stock worth more than $1,202,745 as of February 7th. This net worth estimate does not reflect any other investments that Dr. Miller may own. Learn More about Richard A. Miller 's net worth.
How do I contact Richard A. Miller ?
Has Richard A. Miller been buying or selling shares of Corvus Pharmaceuticals?
Richard A. Miller has not been actively trading shares of Corvus Pharmaceuticals over the course of the past ninety days. Most recently, on Tuesday, December 13th, Richard A. Md Miller bought 50,000 shares of Corvus Pharmaceuticals stock. The stock was acquired at an average cost of $0.74 per share, with a total value of $37,000.00. Following the completion of the transaction, the chief executive officer now directly owns 1,480,119 shares of the company's stock, valued at $1,095,288.06. Learn More on Richard A. Miller 's trading history.
Are insiders buying or selling shares of Corvus Pharmaceuticals?
During the last year, Corvus Pharmaceuticals insiders bought shares 13 times. They purchased a total of 241,050 shares worth more than $249,595.30. The most recent insider tranaction occured on December, 20th when insider William Benton Jones bought 20,000 shares worth more than $15,800.00. Insiders at Corvus Pharmaceuticals own 29.7% of the company.
Learn More about insider trades at Corvus Pharmaceuticals. Information on this page was last updated on 12/20/2022.
Richard A. Miller Insider Trading History at Corvus Pharmaceuticals
| Transaction Date | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 12/13/2022 | Buy | 50,000 | $0.74 | $37,000.00 | 1,480,119 |  |
| 9/28/2022 | Buy | 25,000 | $0.76 | $19,000.00 | 1,394,405 | |
| 9/20/2022 | Buy | 20,000 | $0.81 | $16,200.00 | 1,369,405 | |
| 6/27/2022 | Buy | 5,000 | $1.00 | $5,000.00 | 1,349,405 | |
| 6/24/2022 | Buy | 5,000 | $1.03 | $5,150.00 | 1,344,405 | |
| 6/6/2022 | Buy | 890 | $1.01 | $898.90 | 1,339,405 | |
| 6/2/2022 | Buy | 5,000 | $0.98 | $4,900.00 | 1,338,515 | |
| 3/31/2022 | Buy | 15,000 | $1.64 | $24,600.00 | | |
| 3/17/2022 | Buy | 5,000 | $1.59 | $7,950.00 | | |
| 3/15/2022 | Buy | 25,000 | $1.47 | $36,750.00 | | |
| 8/20/2021 | Buy | 10,000 | $1.93 | $19,300.00 | 35,714 | |
| 2/17/2021 | Buy | 100,000 | $3.50 | $350,000.00 | | |
| 11/12/2019 | Buy | 272 | $2.90 | $788.80 | | |
| 8/7/2019 | Buy | 7,500 | $3.56 | $26,700.00 | | |
| 6/13/2019 | Buy | 343 | $3.52 | $1,207.36 | | |
| 6/11/2019 | Buy | 15,212 | $3.49 | $53,089.88 | | |
| 6/7/2019 | Buy | 9,212 | $3.37 | $31,044.44 | | |
| 12/27/2018 | Buy | 20,000 | $3.29 | $65,800.00 | | |
| 12/27/2018 | Buy | 20,000 | $3.29 | $65,800.00 | | |
| 12/20/2018 | Buy | 10,000 | $4.40 | $44,000.00 | | |
| 12/6/2018 | Buy | 5,000 | $5.99 | $29,950.00 | | |
| 12/4/2018 | Buy | 1,502 | $5.95 | $8,936.90 | | |
| 3/12/2018 | Buy | 100,000 | $8.50 | $850,000.00 | | |
| 11/20/2017 | Buy | 10,000 | $10.79 | $107,900.00 | | |
| 6/13/2017 | Buy | 25,000 | $9.88 | $247,000.00 | | |
| 5/13/2016 | Buy | 30,300 | $10.00 | $303,000.00 | | |
Corvus Pharmaceuticals Company Overview
Corvus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, and Joseph J. Buggy on January 27, 2014 and is headquartered in Burlingame, CA.
Read More
Volume
119,046 shs
Average Volume
110,814 shs
Market Capitalization
$37.83 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.02
